Welcome to Sequence Card of Peptide


Details of CancerPDF entry with Sequence ISASAEELRQRLAPLAEDVRGNL
Primary information
sequence IDSeq_3904
Peptide sequenceISASAEELRQRLAPLAEDVRGNL
CancerPDF_ID CancerPDF_ID78, CancerPDF_ID1077, CancerPDF_ID8581,
PMID16896061,16395409,23667664
Protein NameApolipoprotein A-IV,Apolipoprotein A-IV,Aplipoprotein A-IV
UniprotKB Entry NameAPOA4_HUMAN,APOA4_HUMAN,APOA4_HUMAN
FluidSerum,Serum,Serum
M/Z2508.16,2508.16,2507.35
Charge1,1,1
Mass (in Da)2508.35,NA,2509.83
fdrNA,NA,NA
Profiling TechniqueMALDI-TOF,MALDI-TOF,MALDI-TOF
Peptide Identification techniqueQ/TOF MS/MS,Q/TOF/TOF and LC-MS/MS,FT-ICR MS/MS + nano-HPLC
Quantification TechniqueNA,NA,NA
Labelled/Label FreeLabel Free,Label Free,Label Free
FDRNA,less than 1 “5,NA
CancerPDF_ID CancerPDF_ID78, CancerPDF_ID1077, CancerPDF_ID8581,
p-Value1.00E-05,5.60E-14,NA
SoftwareMASCOT,MASCOT (v 2.0.04 for Windows),MASCOT
Length23,23,23
Cancer TypeMetastatic thyroid carcinomas,"Advanced Prostate, Breast and Bladder cancer","Breast cancer, Lung cancer, Rectal cancer"
DatabaseNCBI refseq Protein Database,NCBI refseq Protein Database,NA
ModificationNA,NA,NA
Number of Patients40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy in training test set, In validation set 41 independent serum samples from patients with advanced prostate cancer (prostate 2 [PR2])","Breast Cancer =84, lung cancer= 70, Rectal cancer = 30patients; 500 healthy"
RegulationNA,"Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.38, 1.2 and 7.96 in prostate, bladder and breast cancer respectively",NA
ValidationIndependent validation,Independent validation,NA
Sensitivity95% on independent dataset,97.5% on independent validation dataset,NA
Specificity95% on independent dataset,NA,NA
AccuracyNA,97.5 % on validation dataset,NA
Peptide AtlasNA
IEDB